See more : PT Pembangunan Graha Lestari Indah Tbk (PGLI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Rani Therapeutics Holdings, Inc. (RANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rani Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kuang Pei San Food Products PCL (POMPUI.BK) Income Statement Analysis – Financial Results
- SECOM CO., LTD. (SOMLF) Income Statement Analysis – Financial Results
- Japan Post Holdings Co., Ltd. (6178.T) Income Statement Analysis – Financial Results
- Nuo Therapeutics, Inc. (AURX) Income Statement Analysis – Financial Results
- Winnebago Industries, Inc. (WGO) Income Statement Analysis – Financial Results
Rani Therapeutics Holdings, Inc. (RANI)
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.72M | 462.00K | 979.00K |
| Cost of Revenue | 822.00K | 1.31M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -822.00K | -1.31M | 2.72M | 462.00K | 979.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.62M | 36.61M | 26.48M | 12.04M | 24.58M |
| General & Administrative | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Cost & Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Interest Income | 3.30M | 1.25M | 89.00K | 63.00K | 423.00K |
| Interest Expense | 5.09M | 1.07M | 466.00K | 124.00K | 10.00K |
| Depreciation & Amortization | 822.00K | 1.31M | 497.00K | 589.00K | 564.00K |
| EBITDA | -65.28M | -60.89M | -52.08M | -15.96M | -26.01M |
| EBITDA Ratio | 0.00% | 0.00% | -1,895.84% | -3,439.83% | -2,663.74% |
| Operating Income | -66.10M | -63.45M | -51.60M | -16.54M | -27.07M |
| Operating Income Ratio | 0.00% | 0.00% | -1,899.12% | -3,580.95% | -2,764.56% |
| Total Other Income/Expenses | -1.78M | 177.00K | -1.45M | -124.00K | 478.00K |
| Income Before Tax | -67.88M | -63.27M | -53.05M | -16.67M | -26.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,952.41% | -3,607.79% | -2,715.73% |
| Income Tax Expense | 0.00 | 70.00K | 41.00K | 35.00K | 10.00K |
| Net Income | -33.97M | -63.34M | -53.09M | -16.70M | -26.60M |
| Net Income Ratio | 0.00% | 0.00% | -1,953.92% | -3,615.37% | -2,716.75% |
| EPS | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| Weighted Avg Shares Out | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
| Weighted Avg Shares Out (Dil) | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
Carallel Raises $8.2 Million to Support Family Caregivers, with Backing from Major Regional Health Plans
CHICAGO--(BUSINESS WIRE)--Carallel, a leading provider of human-centered guidance and digital tools for family caregivers, has raised an $8.2 million Series A funding round. FCA Venture Partners led the round, with participation from prominent regional payers including 450 Ventures, as well...
BOUNDARYLESS 2022 Conference Covering the Future of Remote Work
--(BUSINESS WIRE)--Turing: What: Turing, an AI-powered technology company disrupting the traditional IT services model for companies seeking to source the most deeply vetted developers and teams, is hosting a one day conference, BOUNDARYLESS, to promote dialogue around a broad range...
Sustainable Films for Packaging Market Research Report 2022: A $275+ Billion Industry by 2031 - Global Analysis and Forecast, 2021-2031 with Focus on Materials, Applications, and Regional Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Sustainable Films for Packaging Market - A Global and Regional Analysis: Focus on Material, Applications, and Region - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering. The global sustainable films for packaging market was estimated...
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rani Therapeutics to Present at the Stifel Healthcare Conference
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present...
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
SEATTLE--(BUSINESS WIRE)--Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer. Ms. Baranowski brings more than two decades of experience leading a vast...
Oral Biologics & Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Oral Biologics & Biosimilars Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global oral biologics & biosimilars market is expected to grow from $4.24 billion in 2021 to $5.24 billion in 2022 at a...
Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present...
Global Biodegradable Mulch Films Market (2022 to 2030) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Biodegradable Mulch Films Market by Crop (Grains & Oilseeds, Flowers & Plants), by Raw Material (TPS, PLA, PHA, AAC), by Region (APAC, North America), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global...
Global Mulch Films Market Research Report to 2027 - Featuring Al-Pack Enterprises, Armando Alvarez and BASF Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Mulch Films Market Research Report by Element (Ethylene-vinyl Acetate, High Density Polyethylene, and Linear Low Density Polyethylene), Type, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19"...
Source: https://incomestatements.info
Category: Stock Reports